A phase 3 study of emixustat hydrochloride for stargardt disease IND 101,084 (02/11/2019)
Ended Project Grant Awarded Last action
- Award ID
- R01FD006849
- Recipient
-
Acucela Inc. UEI FNW1T78KSWC1
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $3,268,917
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Funding
-
- $2,723,917.00 Federal
- $545,000.00 Non-federal
- Funding agency
- Office of the Commissioner Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Seattle, WA 98101, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $545,000 | $0 | |
| Amendment | $545,000 | $0 | |
| Amendment | $545,000 | $0 | |
| Amendment | $545,000 | $545,000 | |
| Original award | $543,917 | $0 |
Quick answers
Who received award R01FD006849?
R01FD006849 was awarded to Acucela Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on August 15, 2020.
How much is award R01FD006849 worth?
$3,268,917 has been obligated on R01FD006849: $2,723,917 in federal funding and $545,000 in non-federal funding.
Which agency awarded R01FD006849?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD006849, with funding from Office of the Commissioner (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award